Literature DB >> 18308943

Bone marrow multipotent mesenchymal stromal cells do not reduce fibrosis or improve function in a rat model of severe chronic liver injury.

Adriana B Carvalho1, Luiz Fernando Quintanilha, Juliana V Dias, Bruno D Paredes, Elida G Mannheimer, Felipe G Carvalho, Karina D Asensi, Bianca Gutfilen, Lea Mirian B Fonseca, Celia Maria C Resende, Guilherme F M Rezende, Christina M Takiya, Antonio Carlos Campos de Carvalho, Regina C S Goldenberg.   

Abstract

The objective of our study was to evaluate the therapeutic potential of bone marrow mesenchymal stromal cells (MSC) in a rat model of severe chronic liver injury. Fourteen female Wistar rats were fed exclusively an alcoholic liquid diet and received intraperitoneal injections of carbon tetrachloride every other day during 15 weeks. After this period, eight animals (MSC group) had 1 x 10(7) cells injected into the portal vein while six animals (placebo group) received vehicle. Blood analysis was performed to evaluate alanine aminotransferase (ALT), aspartate aminotransferase (AST), and albumin before cell therapy and 1 and 2 months after cell or placebo infusion. Fibrosis was evaluated before and 1 month after cell or placebo injection by liver biopsies. Two months after cell delivery, animals were sacrificed and histological analysis of the livers was performed. Fibrosis was quantified by histomorphometry. Biopsies obtained before cell infusion showed intense collagen deposition and septa interconnecting regenerative nodules. One month after cell injection, this result was unaltered and differences in fibrosis quantification were not found between MSC and placebo groups. ALT and AST returned to normal values 2 weeks after cell or placebo infusion, without significant differences between experimental groups. Two months after cell or placebo injection, albumin had also returned to normal values and histological results were maintained, again without differences between MSC and placebo groups. Therefore, under our experimental conditions, MSC were unable to reduce fibrosis or improve liver function in a rat model of severe chronic liver injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18308943     DOI: 10.1634/stemcells.2007-0941

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  46 in total

Review 1.  Role of stem cells in repair of liver injury: experimental and clinical benefit of transferred stem cells on liver failure.

Authors:  Mukaddes Esrefoglu
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

Review 2.  Potentials of regenerative medicine for liver disease.

Authors:  Shinichiro Ogawa; Shinichi Miyagawa
Journal:  Surg Today       Date:  2009-12-08       Impact factor: 2.549

Review 3.  Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease.

Authors:  Fernando Ezquer; Flavia Bruna; Sebastián Calligaris; Paulette Conget; Marcelo Ezquer
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  Antifibrotic Activity of Human Placental Amnion Membrane-Derived CD34+ Mesenchymal Stem/Progenitor Cell Transplantation in Mice With Thioacetamide-Induced Liver Injury.

Authors:  Po-Huang Lee; Chi-Tang Tu; Chih-Chiang Hsiao; Ming-Song Tsai; Cheng-Maw Ho; Nai-Chen Cheng; Tzu-Min Hung; Daniel Tzu-Bi Shih
Journal:  Stem Cells Transl Med       Date:  2016-07-12       Impact factor: 6.940

Review 5.  Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases.

Authors:  Hu Lin; Ruonan Xu; Zheng Zhang; Liming Chen; Ming Shi; Fu-Sheng Wang
Journal:  Cell Mol Immunol       Date:  2010-11-22       Impact factor: 11.530

6.  Therapeutic potential of Bama miniature pig adipose stem cells induced hepatocytes in a mouse model with acute liver failure.

Authors:  Shuang Zhang; Zhiqiang Zhu; Yufeng Wang; Shi Liu; Chenqiong Zhao; Weijun Guan; Yuhua Zhao
Journal:  Cytotechnology       Date:  2018-03-07       Impact factor: 2.058

7.  Bone marrow progenitor cells do not contribute to liver fibrogenic cells.

Authors:  Bruno Diaz Paredes; Lanuza Alaby Pinheiro Faccioli; Luiz Fernando Quintanilha; Karina Dutra Asensi; Camila Zaverucha do Valle; Paulo César Canary; Christina Maeda Takiya; Antonio Carlos Campos de Carvalho; Regina Coeli Dos Santos Goldenberg
Journal:  World J Hepatol       Date:  2012-10-27

8.  Ultrasound imaging in an experimental model of fatty liver disease and cirrhosis in rats.

Authors:  Andréia S Lessa; Bruno D Paredes; Juliana V Dias; Adriana B Carvalho; Luiz Fernando Quintanilha; Christina M Takiya; Bernardo R Tura; Guilherme F M Rezende; Antonio C Campos de Carvalho; Célia M C Resende; Regina C S Goldenberg
Journal:  BMC Vet Res       Date:  2010-01-29       Impact factor: 2.741

9.  Effects of mesenchymal stem cells and VEGF on liver regeneration following major resection.

Authors:  Gokhan Adas; Bora Koc; Mine Adas; Gokhan Duruksu; Cansu Subasi; Ozgur Kemik; Ahu Kemik; Damlanur Sakiz; Mustafa Kalayci; Sevim Purisa; Seda Unal; Erdal Karaoz
Journal:  Langenbecks Arch Surg       Date:  2016-04-19       Impact factor: 3.445

10.  Fibrogenic potential of human multipotent mesenchymal stromal cells in injured liver.

Authors:  Reto M Baertschiger; Véronique Serre-Beinier; Philippe Morel; Domenico Bosco; Marion Peyrou; Sophie Clément; Antonino Sgroi; André Kaelin; Leo H Buhler; Carmen Gonelle-Gispert
Journal:  PLoS One       Date:  2009-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.